BRIEF—Novartis reportedly considering shedding derma generics unit

Swiss pharma giant Novartis is considering selling its dermatology generics business, Bloomberg reports.

The news source quotes people familiar with the matter in its report stating that Novartis is looking to offload the unit, which is mainly based in the USA and could fetch up to $1.5 billion, helping it to focus on growth areas such as oncology.

Novartis is said to be working with a financial adviser on the potential disposal, but the Basel-based company has made no comment on the report.